Pharmacokinetic and Efficacy Profile of Low-Dose Intranasal Scopolamine Spray for Motion Sickness
Phase of Trial: Phase II/III
Latest Information Update: 19 Jan 2018
Price : $35 *
At a glance
- Drugs Scopolamine (Primary)
- Indications Motion sickness
- Focus Therapeutic Use
- Sponsors Epiomed Therapeutics; Repurposed Therapeutics
- 16 Nov 2016 Status changed from recruiting to discontinued due to business reasons.
- 12 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 12 Jun 2014 New trial record